Contains A Growth Factor Or Growth Regulator Patents (Class 435/405)
  • Patent number: 10196596
    Abstract: Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: February 5, 2019
    Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: James A. Glazier, Abdelkrim Alileche, Abbas Shirinifard, Dragos Amarie
  • Patent number: 9771559
    Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: September 26, 2017
    Assignee: Stowers Institute for Medical Research
    Inventors: John M. Perry, Linheng Li, Justin C. Grindley
  • Patent number: 9428730
    Abstract: Provided herein are coatings for stem cell cultureware comprising poly-L-ornithine and bovine fibronectin and methods for preparing coated stem cultureware comprising contacting cultureware with poly-L-ornithine and contacting the cultureware with bovine fibronectin. Also provided are stem cell culture media comprising epidermal growth factor, beta-fibroblast growth factor and N2 supplement.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: August 30, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Chenzhong Kuang, Yan Xiao, Zeina Jouni, Eduard K. Poels, Dirk Hondmann
  • Patent number: 9173927
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 3, 2015
    Assignee: STEMNION, INC.
    Inventors: Charlotte A Emig, Catherine J Trumpower, George L Sing
  • Patent number: 9096852
    Abstract: Method of identifying and using compounds which inhibit the expression or activity of micro-RNAs for preventing and/or attenuating ageing, and/or for hydrating skin. An in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin, includes the following steps: a. bringing at least one test compound in contact with a sample of keratinocytes; b. measuring the expression or the activity of at least one microRNA in the keratinocytes; c. selecting the compounds for which an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the expression or an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the activity of at least one microRNA is measured in the keratinocytes treated in a. compared with the untreated keratinocytes.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: August 4, 2015
    Assignee: CHANEL PARFUMS BEAUTE
    Inventors: Eleonora Candi, Gennaro Melino, Gaelle Saintigny, Christian Mahe
  • Patent number: 9029146
    Abstract: We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: May 12, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Sai Kiang Lim, Elias Lye
  • Patent number: 8999707
    Abstract: This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: April 7, 2015
    Assignee: Thomas Jefferson University
    Inventors: Scott K. Dessain, Sharad P. Adekar
  • Publication number: 20150093784
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 2, 2015
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang D. Chang, Thomas Seewoester
  • Patent number: 8993323
    Abstract: The present invention is directed to a method of deriving pluripotent embryonic stem cells from mouse blastocysts or from primordial germ cells from a post-implantation mouse embryo, or of maintaining or growing pluripotent embryonic stem cells from a mouse, or of expanding human hematopoietic stem cells or human hematopoietic precursor cells. The methods include the step of cultivating the stem cells or precursor cells for at least one passage in a culture medium preconditioned by the rabbit fibroblast cell line Rab9 (ATCC catalogue CRL1414) and containing less than 0.1 ng/ml Leukemia Inhibitory Factor (LIF).
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: March 31, 2015
    Assignee: ThromboGenics N.V.
    Inventor: Luc Schoonjans
  • Patent number: 8993326
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: March 31, 2015
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20150087060
    Abstract: An object of the present invention is to provide a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells. The above object is achieved by providing a method for inducing the differentiation of erythropoietin-producing cells from human pluripotent stem cells using a medium containing a specific growth factor and a specific compound.
    Type: Application
    Filed: April 4, 2013
    Publication date: March 26, 2015
    Applicant: Kyoto University
    Inventors: Kenji Osafune, Hirofumi Hitomi
  • Publication number: 20150087024
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Application
    Filed: December 8, 2014
    Publication date: March 26, 2015
    Inventors: ITZCOATL A. PLA, JOSEPH G. MATUCK, JOHN C. FANN, CHRISTOF SCHULZ, NICHOLE A. ROY, DAVID F. BRUTON, JAMES MCLNTIRE, YU-HSIANG D. CHANG, THOMAS SEEWOESTER
  • Patent number: 8962325
    Abstract: Cell culture media formulations for culturing human epithelial cells are herein described. Also described are methods of increasing population doublings in a cell culture of finite life span human epithelial cells and prolonging the life span of human cell cultures. Using the cell culture media disclosed alone and in combination with addition to the cell culture of a compound associated with anti-stress activity achieves extended growth of pre-stasis cells and increased population doublings and life span in human epithelial cell cultures.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: February 24, 2015
    Assignee: The Regents of the University of California
    Inventors: Martha R. Stampfer, James C. Garbe
  • Patent number: 8956830
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 17, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Publication number: 20150044176
    Abstract: The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for hematopoietic transplantation.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 12, 2015
    Applicant: FATE THERAPEUTICS, INC.
    Inventor: Betsy Denise REZNER
  • Patent number: 8945925
    Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: February 3, 2015
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Publication number: 20150030634
    Abstract: The purpose of the present invention is to provide a means for proliferating a monocyte with high efficiency and in a simple manner. The present invention provides a proliferating agent for a monocyte, which consists of at least one component selected from Flt-3L, IL-3 and IFN-? and can be used before a treatment for differentiation of a monocyte into a dendritic cell. The present invention also provides a culture medium for use in the proliferation of a monocyte, which contains at least one component selected from Flt-3L, IL-3 and IFN-? and can be used before a treatment for differentiation of a monocyte into a dendritic cell. The culture medium for use in the proliferation of a monocyte according to the present invention may contain GM-CSF.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 29, 2015
    Inventors: Hiroyuki Abe, Hiroaki Kawasaki
  • Patent number: 8940537
    Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: January 27, 2015
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Benjamin Reubinoff, Debora Steiner
  • Publication number: 20150024491
    Abstract: An object of the present invention is to develop and provide a method for producing a neuron model having reproduced in vivo properties by improving a cell culture medium composition and a cell culture medium composition necessary for the production of such neuron model. According to the present invention, cell culture is carried out in vitro using a medium for producing in vivo-like and enhanced synaptogenesis neuron model supplemented with a medium supplement for producing in vivo-like and enhanced synaptogenesis neuron model comprising any or any combination of NT-3, potassium or a salt thereof, and FGF2.
    Type: Application
    Filed: March 27, 2012
    Publication date: January 22, 2015
    Applicant: OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY
    Inventors: Dimitar Ivanov Dimitrov, Laurent Elie Guillaud, Zacharie Mehdi Francois Taoufiq, Tomoyuki Takahashi
  • Patent number: 8936939
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: January 20, 2015
    Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Publication number: 20150017134
    Abstract: In some aspects, compositions and methods useful for generating stem cells from epithelial cells are disclosed.
    Type: Application
    Filed: March 1, 2013
    Publication date: January 15, 2015
    Inventors: Wenjun Guo, Robert A. Weinberg, Zuzana Keckesova
  • Publication number: 20150017726
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Application
    Filed: April 16, 2014
    Publication date: January 15, 2015
    Applicant: Minerva Biotechnologies Corporation
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Patent number: 8927276
    Abstract: The present invention relates to a simplified process, which is shorter in time, for propagation of proliferating cells, such as e.g. progenitor or stem cells, by means of a biphasic culturing system having a differentiation supporting component and a proliferation supporting component, and to the use of the stem cell cultures obtained in this way for cell therapy purposes. The present invention invention describes a method, which is highly efficient to prime stem or progenitor cells to differentiation using non-attachment matrices and differentiation supporting component. The cells produced therefrom may be used to treat a variety of neurodegenerative disorders.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: January 6, 2015
    Assignee: Cellin Technologies OUE
    Inventors: Kaia Palm, Toomas Neuman
  • Publication number: 20150004146
    Abstract: Methods of culturing mesenchymal stem cells are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide and fibroblast growth factor 4 (FGF4). Populations of mesenchymal stem cells generated using the methods described herein and uses thereof are also provided.
    Type: Application
    Filed: February 13, 2012
    Publication date: January 1, 2015
    Applicant: Gamida-Cell Ltd.
    Inventors: Tony Peled, Yair Steinhardt
  • Patent number: 8911997
    Abstract: A cell culture medium and system are provided which eliminate or at least reduce the requirement for exogenous components such as serum and feeder cells. The cell culture medium comprises an IGF and vitronectin or fibronectin and, optionally an IGFBP, and is particularly suitable for propagating keratinocytes for subsequent use in skin growth and regeneration. This invention also relates to compositions and methods for skin growth and regeneration in situ, which utilize aerosol delivery of cultured keratinocytes.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: December 16, 2014
    Assignee: Queensland University of Technology
    Inventors: Zee Upton, Damien Harkin, David Leavesley
  • Patent number: 8911994
    Abstract: Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: December 16, 2014
    Assignee: Artecel Sciences Inc.
    Inventors: Yuan-Di C. Halvorsen, William O. Wilkison, Jeffrey Martin Gimble
  • Publication number: 20140363886
    Abstract: The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 11, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES, UNIVERSITE DE STRASBOURG, CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
    Inventors: Olivier Pourquie, Jérôme Chal
  • Patent number: 8906689
    Abstract: The present invention relates to variant endoglucanases having improved thermoactivity, improved thermostability, and improved viscosity reduction activity over wild-type M. thermophila endoglucanase.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 9, 2014
    Assignee: Codexis, Inc.
    Inventors: Xiyun Zhang, Sachin Patil, Jie Yang, Ish Kumar Dhawan
  • Publication number: 20140356945
    Abstract: The present invention relates to a type of cell—potential regenerative cell (PRC) capable of continuous proliferation, and generated mammal (including human) cells, tissues and tissue-organs by in vitro culture and replication of PRCs. The present invention also relates to the methods and cell growth regulators for culturing mammal (including human) PRCs, tissues, and tissue-organs.
    Type: Application
    Filed: August 15, 2014
    Publication date: December 4, 2014
    Inventor: Xu Rongxiang
  • Publication number: 20140356368
    Abstract: The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. Here, the ISRAA polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders.
    Type: Application
    Filed: October 12, 2012
    Publication date: December 4, 2014
    Applicant: ARABIAN GULF UNIVERSITY
    Inventors: Abdelmoiz Bakhiet, Safa Taha
  • Patent number: 8900868
    Abstract: A medium for growing vascular lineage cells is described. The vascular lineage cell growth medium includes an oligosaccharide-based hydrogel and a growth factor that promotes vascularization by vascular lineage cells.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: December 2, 2014
    Assignee: The Johns Hopkins University
    Inventors: Donny Hanjaya-Putra, Sharon Gerecht
  • Patent number: 8883504
    Abstract: The object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell, a method for culturing using the same, a cell culture liquid using the same, and a cell prepared by culturing using this differentiation inhibiting agent. The present invention provides a differentiation inhibiting agent which comprises a low molecular weight compound, especially a tetrahydroisoquinoline derivative, as an active ingredient; a method for safely culturing a stem cell in large scale in undifferentiated state in the absence of feeder cell which comprises culturing a stem cell by using a tetrahydroisoquinoline derivative; a culture liquid for stem cells comprising a tetrahydroisoquinoline derivative; and a cell which is obtained by culture using a tetrahydroisoquinoline derivative as a differentiation inhibiting agent.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: November 11, 2014
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventors: Tomoyuki Miyabayashi, Masashi Yamamoto
  • Publication number: 20140328808
    Abstract: It is an object of the present invention to provide a culture medium for in vitro culture of a colorectal epithelial stem cell or the like, a method of in vitro culturing a colorectal epithelial stem cell or the like using the culture medium, a prophylactic or therapeutic agent for a bowel disease containing a colorectal epithelial stem cell or the like cultured by the method, a method of administrating, i.e., transplanting a colorectal epithelial stem cell or the like cultured by the method to a bowel disease patient, and a method of isolating a colorectal epithelial stem cell or the like. The culture medium for in vitro culture of a colorectal epithelial stem cell and/or a colorectal epithelial cell characteristically contains serum albumin, Wnt3a, and r-spondin-1.
    Type: Application
    Filed: October 26, 2012
    Publication date: November 6, 2014
    Applicant: National University Corporation Tokyo Medical and Dental University
    Inventors: Mamoru Watanabe, Tetsuya Nakamura
  • Patent number: 8871513
    Abstract: The present invention relates to a medium for culturing mesenchymal stem cells, and more particularly to a medium composition for culturing mesenchymal stem cells, which contains basal medium, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factor (b-FGF), non-essential amino acids (NEAAs), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone, and a method of culturing mesenchymal stem cells using the same. According to the present invention, a number of mesenchymal stem cells required for stem cell therapy can be obtained in a short time, and the ability of mesenchymal stem cells to differentiate is improved so that they are useful for stem cell therapy.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: RNL Bio Co., Ltd.
    Inventors: Jeong Chan Ra, Sung Keun Kang, Ju Yeon Seo, Hyoeun Kim
  • Patent number: 8846400
    Abstract: A cell culture comprising human foreskin cells, the human foreskin cells being capable of maintaining stem cells in an undifferentiated state when co-cultured therewith.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: September 30, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Michal Amit, Joseph Itskovitz-Eldor
  • Publication number: 20140286915
    Abstract: The present invention relates to hematopoietic cells, and more specifically to methods for long-term in vitro culturing and ex vivo expansion of hematopoietic cells. The present invention also provides compositions useful for culturing cells, such as media for culturing hematopoietic cells, specifically haematopoietic stem cells (HSC) and haematopoietic progenitor cells (HPC). The present invention further provides compositions including growth factor combinations and methods utilising altered growth and environmental conditions that are applicable in vitro culturing and to ex vivo expansion of HSC and/or HPC.
    Type: Application
    Filed: September 21, 2012
    Publication date: September 25, 2014
    Applicant: CYTOMATRIX PTY LTD
    Inventors: Melinda L. Tursky, Mark A. Kirkland
  • Publication number: 20140287501
    Abstract: This invention provides disc stem cells, processes for obtaining and culturing disc stem cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 25, 2014
    Applicant: DISCGENICS
    Inventors: Valery Kukekov, Umar Akbar, Christopher Duntsch
  • Publication number: 20140273212
    Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 18, 2014
    Applicant: Taiga Biotechnologies, Inc.
    Inventors: BRIAN CURTIS TURNER, YOSEF REFAELI, GREGORY BIRD
  • Patent number: 8835176
    Abstract: The invention relates to the cell disruption of microbes and the preparation of the microbe proteins for mass spectrometric analysis. The cells of microbes from microcolonies are disrupted by physical or chemical means directly on the nutrient medium. The released proteins are then transferred to sample supports by direct contact with their contact surfaces; electrophoresis can be used for assistance. Once the proteins are firmly adsorbed on the contact surfaces, they can be washed with water in order to remove substances which interfere with the ionization process. For analysis by matrix-assisted laser desorption (MALDI), the proteins are prepared on the contact surfaces of the sample supports with matrix substances to form MALDI samples; the sample supports are then introduced into a MALDI mass spectrometer for the acquisition of mass spectra. The microbes are identified by similarity comparisons between the mass spectra of the microbe proteins and similarly obtained reference spectra.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 16, 2014
    Assignee: Bruker Daltonik GmbH
    Inventors: Jens Boβmeyer, Jochen Franzen
  • Patent number: 8835175
    Abstract: A culture medium for human mesenchymal stem cells (hMSC) includes a mesenchymal stem cell basal medium; human leucocyte/platelet coat lysate; insulin; sodium selenite; ethanolamine; and basic fibroblast growth factor. This culture medium is effective for growing hMSC lines, including those which do not grow in culture medium normally used for this type of cell.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 16, 2014
    Assignee: Grifols, S.A.
    Inventors: Jose Maria Diez Cervantes, Rodrigo Gajardo Rodriguez
  • Patent number: 8822212
    Abstract: A method for forming at least a tooth root in a tooth containing a tooth crown, including: forming a culture core containing the tooth and a cell-containing base material, the tooth being wrapped with the cell-containing base material, and culturing the culture core in a medium to form at least the tooth root in the tooth contained therein, wherein the cell-containing base material contains at least one kind of cells selected from periodontal ligament-derived cells, bone marrow-derived cells, dental follicle-derived cells, dental pulp-derived cells and dental papilla-derived cells, and the medium contains a component contained in a conditioned medium of a serum-free-cultured cell line of a human uterocervical squamous carcinoma cell line; an additive containing at least one selected from IL-1?, IL-6, IL-8, IL-9, EGF, IGF-I, GH, PDGF-AB, VEGF, LIF, HGF, FGF-2, FGF-1, BMP-2, BMP-4, M-CSF, dexamethasone, insulin, thyroxine, thyrocalcitonin, ascorbic acid and ?-glycerophosphate; or both of them.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: September 2, 2014
    Assignee: The Nippon Dental University
    Inventors: Taka Nakahara, Hiroshi Ishikawa, Soh Sato, Masato Ohta
  • Patent number: 8815584
    Abstract: The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (DETA); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: August 26, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: James J. Hickman, Mainak Das
  • Patent number: 8815588
    Abstract: We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: August 26, 2014
    Assignee: Agency for Science, Technology and Research
    Inventors: Sai Kiang Lim, Elias Lye
  • Publication number: 20140234905
    Abstract: The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.
    Type: Application
    Filed: March 26, 2014
    Publication date: August 21, 2014
    Applicant: AbbVie Inc.
    Inventors: Itzcoatl A. Pla, Joseph G. Matuck, John C. Fann, Christof Schulz, Nichole A. Roy, David F. Bruton, James McIntire, Yu-Hsiang David Chang, Thomas Seewoester
  • Patent number: 8796025
    Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: August 5, 2014
    Assignee: Stemnion, Inc.
    Inventors: Charlotte A Emig, Catherine J Trumpower, Vivienne S Marshall
  • Publication number: 20140206029
    Abstract: The present invention relates to a tubule forming platform and an in vitro cardiovascular model for use in pharmacological studies. Furthermore, the invention relates to methods for the preparation said platform and model, and to a method of determining a biological activity of a test substance in said platform and cardiovascular model. Still further, the invention relates to an implantable cardiac structure for use in the treatment of cardiac disorders.
    Type: Application
    Filed: June 14, 2012
    Publication date: July 24, 2014
    Applicant: TAMPEREEN YLIOPISTO
    Inventors: Katriina Aalto-Setälä, Tuula Heinonen, Erja Kerkelä, Jertta-Riina Sarkanen, Hanna Vuorenpää, Timo Ylikomi
  • Publication number: 20140206082
    Abstract: Provided is a composition for embryo culture, which contains a constitution suitable for embryo culture. Provided is a composition for embryo culture, which contains (a) a constitution shown in Table A below. TABLE A Components mM L-Alanine 0.297 ± 0.089 L-Asparagine 0.015 ± 0.005 L-Aspartic acid 0.120 ± 0.036 L-Glutamic acid 0.550 ± 0.165 Glycine 0.979 ± 0.294 L(?)-Proline 0.105 ± 0.032 L-Serine 0.176 ± 0.053 L(+)-Arginine 0.108 ± 0.032 L(?)-Cystine 0.048 ± 0.014 L-Histidine 0.053 ± 0.016 L(+)-Isoleucine 0.036 ± 0.011 L-Leucine 0.081 ± 0.024 L(+)-Lysine 0.176 ± 0.053 L-Methionine 0.022 ± 0.007 L(?)-Phenylalanine 0.045 ± 0.013 L(?)-Threonine 0.109 ± 0.033 L-Tryptophan 0.018 ± 0.005 L-Tyrosine 0.048 ± 0.014 L-Valine 0.108 ± 0.032 L-Glutamine or 0.398 ± 0.119 glutamine derivative Taurine 1.412 ± 0.
    Type: Application
    Filed: July 18, 2012
    Publication date: July 24, 2014
    Applicant: FUSO PHARMACEUTICAL INDUSTRES, LTD.
    Inventors: Tatsuma Yao, Yuta Asayama, Akio Matsuhisa
  • Patent number: 8772460
    Abstract: Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 8, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Guokai Chen, James A. Thomson, Zhonggang Hou
  • Patent number: 8765464
    Abstract: The present invention provide: a novel process for culturing animal cells and a kit for culturing animal cells, in which, even if the number of cells as sampled for biopsy is extremely small, the proliferation can sufficiently be maintained so as to enable to carry out various culture and/or tests, especially anticancer agent sensitivity tests, and the contamination with bacteria can be inhibited without damaging physiological activity of cells, especially sensitivity to anticancer agents. The process for culturing animal cells, according to the present invention, comprises the step of culturing a sample containing animal cells obtained from living body tissue in order to subject the sample to further culture and/or a test, with the process being characterized in that a culture medium is used wherein the culture medium has a proliferating action and physiological activity-retaining action on the animal cells, and further has a killing action and/or multiplication-inhibition action on bacteria.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: July 1, 2014
    Assignee: Kurashiki Boseki Kabushiki Kaisha
    Inventors: Kazuhiko Minamigawa, Hisayuki Kobayashi, Toshikazu Takano
  • Patent number: 8765465
    Abstract: This invention relates to a method for producing cardiomyocytes and/or cardiac progenitor cells, comprising culturing an induced pluripotent stem (iPS) cell or embryonic stem (ES) cell, which has been differentiated into a mesoderm cell, in the presence of cyclosporin-A.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: July 1, 2014
    Assignee: Kyoto University
    Inventors: Jun Yamashita, Peishi Yan